Enabling Targeted Delivery
with Synthetic Carriers
FINNCURE enables pharmaceutical and biotech companies to improve therapeutic targeting with its high-performance synthetic carriers.
Discover More
The Shift from Viral to Synthetic Delivery
Since the early 1970s, viral vectors have transformed the treatment of genetic disorders and helped advance personalized medicine. However, viral carriers face important limitations including toxicity, immunogenicity, and the risk of insertional mutagenesis. Their production is also complex, with significant challenges related to regulatory requirements, quality control, and scalability.
The success of mRNA vaccines drew attention to the potential of non-viral delivery technologies. Lipid nanoparticles and other synthetic carriers can carry therapeutic compounds with high payload capacity, favorable safety profiles, and scalable manufacturing.
Even with these advances, achieving precise targeting, efficient cellular uptake, and consistent particle characteristics remains a challenge. FINNCURE was founded to solve these problems through receptor-targeted carrier systems and precision manufacturing.
01
A Platform for
Targeted Delivery
FINNCURE develops functionalized carrier particles that selectively bind to target receptors, enabling precise delivery of therapeutic compounds, as well as receptor-level blocking to prevent pathogen entry into cells. The platform is designed for reproducible and scalable manufacturing. While current development is focused on lipid nanoparticles, the technology is not limited to lipid-based systems.
02
Multiple Therapeutic
Applications
The carrier platform can incorporate a broad range of therapeutic payloads and be adapted to different receptor targets, carrier materials, and administration routes. This allows the technology to be used across targeted therapeutics, infectious disease prevention, and gene-based therapies.
03
Validated in
Preclinical Studies
Preclinical studies conducted at Charles River Laboratories and Tebubio have demonstrated receptor-specific localization, high target tissue uptake, minimal off-target accumulation, inhibition of viral entry, and favorable tolerability.
04
Partnering to Improve
Therapeutic Delivery
We work with pharmaceutical and biotech companies to integrate their therapeutic compounds into the carrier platform, addressing targeting, cellular uptake, and off-target exposure. Development is supported by a network of experienced scientific and industry partners.
Let's Build
the Future Together
Partner with us to explore new ways to improve the targeting and delivery of therapeutic compounds through collaboration, development, and licensing opportunities.
Become a partner